Open AccessLocalization of Small‐cell Lung Cancer Xenografts with Iodine‐125‐, Indium‐111‐, and Rhenium‐188‐Somatostatin Analogs
Author(s) -
Hosono Makoto,
Hosono Masako N.,
Haberberger Thomas,
Zamora Paul O.,
Guhlke Stefan,
Bender Hans,
Russ Knapp F. F.,
Biersack Hans J.
Publication year - 1996
Publication title -
japanese journal of cancer research
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.035
H-Index - 141
eISSN - 1349-7006
pISSN - 0910-5050
DOI - 10.1111/j.1349-7006.1996.tb02131.x
Subject(s) - octreotide , somatostatin , endocrinology , medicine , chemistry
We examined the potential of radiolabeled somatostatin analogs, 125 I‐Tyr‐3‐octreotide ( 125 I‐octreotide), 111 In‐DTPA(diethylenetriaminepentaacetatic acid)‐ d ‐Phe‐1‐octreotide ( 111 In‐octreotide), and 188 Re‐octreotide for targeting small‐cell lung cancer (SCLC) in a mouse model. Tyr‐3‐octreotide was labeled with 125 I by the chloramine T method, and 111 In‐octreotide was obtained as a kit, while 188 Re was eluted from a 188 W/ 188 Re generator, and octreotide was directly labeled with 188 Re by reducing disulfide bonds. The 125 I‐, 111 In‐, and 188 Re‐octreotides were injected i.v. into athymic mice bearing NCI‐H69 tumors, and the biodistributions were determined at 15 min, and 2, 4, 8, and 24 h. Tumor uptakes were 0.5±0.2, 0.3±0.1, 0.3±0.1 %ID/g, and tumor‐to‐blood ratios were 1.8, 11.9, 1.2 at 8 h for 125 I‐, 111 In‐, and 188 Re‐octreotides, respectively. Accumulations of 111 In‐octreotide in normal tissues were lower than those of 125 I‐ and 188 Re‐octreotides. 188 Re‐octreotide can be used to localize SCLC lesions as efficiently as radioiodinated octreotide. However, 111 In‐octreotide was the most suitable agent to obtain high tumor‐to‐normal tissue contrast for localizing SCLC.